Author bullish on SLS expecting a successful cancer trial to boost the stock from $4 to $20 in the next couple months.
SLS — LONG SLS is a biotech whose cancer treatment is about to finish a successful trial, which the author expects to propel the stock from $4 to $20 in the next couple months. The catalyst is the trial completion/readout.
SLS is a biotech with a cancer treatment thats about to finish a successful trial which will propell its sock from $4 to 20 in the next couple months.
This Reddit post, published January 04, 2026, features u/Blue_Smoke369 discussing SLS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Blue_Smoke369 · Tickers: SLS